Request for information relating to adrenaline auto-injectors
In November 2014 PHARMAC issued a request for information (RFI) from suppliers and wholesalers who may be interested in pursuing a listing agreement with PHARMAC for the supply of adrenaline auto-injectors in the community and DHB hospitals.
In particular we were interested in obtaining information from suppliers about the different types of adrenaline auto-injectors available and indicative pricing based upon the recommended funding criteria.
We are grateful for the information that has been provided to us from this process. As a result we think there will be competition available in the near future to enable us to run a request for proposals (RFP). No feedback was received regarding the proposed Special Authority criteria.
If you have any questions about this information, you can email us at email@example.com or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Adrenaline ampoules are currently listed and fully funded for supply in the community and DHB hospitals without any restrictions.
PHARMAC does not currently fund adrenaline in an auto-injector delivery device.
PHARMAC has received a number of funding applications for adrenaline auto-injectors for the treatment of anaphylaxis caused by allergies to venom, food or any other antigens. These have been reviewed by the Pharmacology and Therapeutics Advisory Committee (PTAC) - https://connect.pharmac.govt.nz/apptracker/s/global-search/adrenaline%20auto-injectors. The most recent funding application was considered during the May 2014 PTAC meeting.
At its May 2014 meeting, PTAC recommended funding one adrenaline auto-injector over a 12 month period for people who have previously experienced an anaphylactic reaction to venom or food with a medium priority. PTAC recommended that funding should be subject to patients being fully trained in the use of an auto-injector and having an anaphylaxis action plan.